Our favorable outlook for the biotechnology industry remains intact for 2012 and is based on several key drivers
2012 Preview: Cancer Immunotherapy Catalysts
December 14, 2011 By 1 Comment
2012 represents a period with robust news flow for emerging immuno-oncology companies
Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution
September 18, 2011 By Leave a Comment
Often overlooked, adjuvants can be an essential part of an effective vaccine and could help advance the field of cancer immunotherapy even further.
Similarities Between Two Immunotherapies in Cancer
March 30, 2011 By 1 Comment
Approval of Bristol-Myers Squibb’s Yervoy® [ipilimumab] for melanoma in March 2011 marked the second victory for the field of immunotherapy in oncology within a year.
Ipilimumab Approval Highlights Immunotherapy Renaissance
March 25, 2011 By Leave a Comment
On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.
Follow MD Becker Partners